EPOR Antibody

What is the EPOR antibody and what is its target protein?

EPOR antibodies are immunological reagents designed to recognize and bind to the Erythropoietin Receptor, a glycoprotein belonging to the type I superfamily of single-transmembrane cytokine receptors. The EPOR consists of an extracellular domain that binds erythropoietin (EPO), a transmembrane domain, and an intracellular domain. Upon EPO binding, EPOR triggers the activation of several signaling pathways that induce erythropoiesis, including JAK2/STAT5, PI3K/AKT, and MAPK pathways . EPOR is primarily expressed on erythroid progenitor cells but has also been detected in various non-hematopoietic tissues . Different EPOR antibodies may target specific domains or epitopes of the receptor, including the extracellular domain, intracellular domain, or specific phosphorylation sites, making antibody selection critical for experimental success.

What applications are EPOR antibodies validated for?

EPOR antibodies can be utilized across multiple research applications with varying degrees of efficacy:

It's crucial to select antibodies specifically validated for your application of interest. For example, some antibodies perform well in Western blot but poorly in immunohistochemistry applications . The EpoCan consortium has developed monoclonal antibodies specifically validated across multiple applications .

What is the expected molecular weight of EPOR protein in laboratory experiments?

This molecular weight discrepancy has been a source of confusion in EPOR research and contributed to misidentification issues. In a notable investigation, Elliott and colleagues demonstrated that several commercially available antibodies that detected proteins in the 66-78 kDa range were actually binding to non-EPOR proteins . For instance, the C-20 antibody was found to detect heat shock protein (HSP70) at 66 kDa, which was mistakenly identified as EPOR in numerous studies .

When performing Western blot analysis, researchers should expect bands at both the calculated (55 kDa) and post-translationally modified (66-78 kDa) sizes, with validation through appropriate controls to confirm specificity.

How should EPOR antibodies be stored for optimal performance?

Proper storage of EPOR antibodies is critical for maintaining their specificity and sensitivity. Storage conditions can vary between products, but generally follow these guidelines:

To maintain antibody performance:

• Minimize freeze-thaw cycles, which can degrade antibody quality

• Store in the dark to prevent light-induced degradation

• Follow specific manufacturer recommendations for each product

• Monitor antibody performance over time using consistent positive controls

How do I validate the specificity of an EPOR antibody?

Validating EPOR antibody specificity is particularly important given the historical challenges with non-specific binding. A comprehensive validation strategy includes:

• Multiple technique comparison: Test antibody performance across different methods (Western blot, immunoprecipitation, flow cytometry) to confirm consistent detection patterns.

• Molecular weight verification: Confirm that detected protein has the expected molecular weight profile of EPOR (calculated 55 kDa, observed 66-78 kDa).

• Controls assessment:

  • Positive controls: Use cell lines with confirmed EPOR expression (HepG2, Jurkat, K-562 cells)

  • Negative controls: Include cells with minimal EPOR expression

  • EPOR-transfected cells: Compare transfected versus non-transfected cells

• Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding. In a landmark study, Elliott et al. used this approach to demonstrate that the C-20 antibody was detecting HSP70 rather than EPOR .

• Genetic manipulation: Employ siRNA knockdown or CRISPR knockout of EPOR to demonstrate reduced antibody binding.

• Cross-reactivity assessment: Evaluate potential binding to similar proteins, especially since some anti-EPOR antibodies cross-react with heat shock proteins .

• Mass spectrometry confirmation: For definitive validation, immunoprecipitate the detected protein and confirm its identity.

The persistent use of non-validated antibodies has led to significant controversies in EPOR research, particularly regarding its expression in cancer tissues .

What are the optimal conditions for using EPOR antibodies in Western blotting?

Achieving optimal Western blot results with EPOR antibodies requires attention to several technical factors:

• Sample preparation:

  • Complete lysis using buffers containing appropriate detergents (RIPA or NP-40)

  • Include protease inhibitors to prevent degradation

  • For phosphorylation studies, add phosphatase inhibitors

  • Denature samples thoroughly at 95-100°C in sample buffer with reducing agent

• Gel electrophoresis:

  • Use gradient gels (e.g., 4-15%) to optimize resolution around 55-78 kDa range

  • Include molecular weight markers that span the expected EPOR size range

  • Load appropriate positive controls (e.g., HepG2, Jurkat, K-562 cells)

• Transfer conditions:

  • Optimize transfer time and voltage for proteins in the 55-78 kDa range

  • Consider semi-dry or wet transfer methods based on laboratory capabilities

• Antibody incubation:

  • For antibody 55308-1-AP, dilute 1:500-1:1000 in blocking buffer

  • Optimize primary antibody incubation (typically overnight at 4°C)

  • Use appropriate secondary antibody at manufacturer-recommended dilution

• Detection system:

  • Choose chemiluminescent, fluorescent, or colorimetric detection based on sensitivity requirements

  • For weak signals, consider enhanced chemiluminescent substrates or signal amplification systems

• Controls:

  • Include lysate from EPOR-transfected cells as positive control

  • Run negative control samples in parallel

  • Consider peptide competition controls to confirm specificity

• Interpretation:

  • Look for specific bands at expected molecular weights (55 kDa calculated, 66-78 kDa observed)

  • Be aware that post-translational modifications may result in multiple bands

  • Verify any unexpected bands through additional validation experiments

The historical specificity issues with EPOR antibodies underline the importance of thorough validation in Western blotting applications.

What methodologies are recommended for measuring anti-EPOR autoantibodies in clinical samples?

Detection of anti-EPOR autoantibodies in patient samples requires specialized approaches as demonstrated in multiple clinical studies:

• Enzyme-Linked Immunosorbent Assay (ELISA):

  The most widely used method employs these key steps:

  a) Antigen coating: Recombinant human EPOR protein (R&D Systems) is coated onto microplates at 5 μg/ml in sodium bicarbonate buffer .

  b) Blocking: Free binding sites are blocked with 1% bovine serum albumin in phosphate-buffered saline .

  c) Sample application: Patient serum samples are diluted 1000-fold and applied to wells . Some protocols use a 1:1000 dilution for screening studies .

  d) Detection system: Anti-human IgG conjugated with horseradish peroxidase is applied, followed by tetramethylbenzidine substrate .

  e) Quantification: Results are expressed in ELISA units (EU) using a standard curve from control serum or as optical density ratios between patient and control samples .

  f) Positivity threshold: Various studies use different cut-offs:

  • ≥2 EU in diabetic nephropathy studies

  • OD450 ratio >1.5 in hemodialysis studies

• Statistical Analysis Approaches:

  Clinical studies analyzing anti-EPOR antibodies employ various statistical methods:

  • Standard comparisons using t-tests or Mann-Whitney U-tests for continuous variables

  • Chi-square tests for categorical variables

  • Multivariable Cox proportional hazards for survival outcomes

  • Linear and logistic regression models for continuous and binary outcomes

  • Adjustment for confounding variables such as age, sex, kidney function, and comorbidities

Notably, the prevalence of anti-EPOR antibodies varies by population: 4.5% in hemodialysis patients , 7.3% in patients with type 2 diabetes and CKD , and 23% in diabetic nephropathy patients .

How do EPOR antibodies perform across different detection systems and platforms?

The performance of EPOR antibodies varies significantly across different detection systems, requiring careful selection for specific applications:

The EpoCan consortium developed and characterized 25 murine and rat monoclonal antibodies against EPOR, systematically evaluating their performance across applications . Their findings indicated that only selected antibodies demonstrated sufficient specificity across multiple platforms.

For immunohistochemistry applications, which have been particularly problematic, careful validation is essential. Elliott and colleagues demonstrated that many commercially available antibodies were unsuitable for IHC detection of EPOR, contributing to misinterpretation of EPOR expression in cancer tissues .

Cross-platform validation, where results from different detection methods are compared, provides the most robust approach to EPOR detection and characterization.

How do anti-EPOR autoantibodies affect clinical outcomes in patients with kidney disease?

Anti-EPOR autoantibodies have emerged as significant biomarkers in kidney disease, with consistent associations across multiple studies:

• Risk of Kidney Disease Progression:
  In the CREDENCE trial involving patients with type 2 diabetes and CKD:

  • 7.3% of participants were positive for anti-EPOR antibodies

  • Higher baseline anti-EPOR antibodies were associated with increased risk of the primary kidney outcome (HR per 1-SD increase = 1.12, 95% CI = 1.01–1.24, P = 0.04)

  • This association remained significant after adjusting for kidney function parameters and cardiovascular risk factors

• Mortality Outcomes:
  Anti-EPOR antibodies were linked to increased risk of:

  • Cardiovascular death (HR = 1.27, 95% CI = 1.08–1.48, P < 0.01)

  • All-cause mortality (HR = 1.26, 95% CI = 1.11–1.43, P < 0.01)

• Anemia and EPO Resistance:

  • Patients with anti-EPOR antibodies had lower hemoglobin levels

  • Higher erythropoietin resistance index (13.00 vs. 5.75, P = 0.026)

  • Required higher doses of erythropoiesis-stimulating agents (7500 vs. 4000 units/weekly, P = 0.049)

• Inflammatory Markers:

  • Anti-EPOR antibodies were associated with increased C-reactive protein levels (0.33 mg/dL vs. 0.15 mg/dL, P = 0.028)

  • In vitro studies showed that IgG fractions containing anti-EPOR antibodies upregulated monocyte chemoattractant protein-1 expression in tubular epithelial cells under high glucose conditions

• Response to Treatment:

  • The SGLT2 inhibitor canagliflozin increased hemoglobin and hematocrit consistently regardless of anti-EPOR antibody status (P-interaction = 0.24 and 0.36, respectively)

These findings suggest that screening for anti-EPOR antibodies could identify high-risk patients who might benefit from more intensive monitoring and treatment. The pathophysiological mechanisms linking these antibodies to adverse outcomes warrant further investigation.

What are the most common challenges in interpreting EPOR antibody research results?

Interpreting EPOR antibody research results presents several significant challenges that researchers must navigate:

To address these challenges, researchers should:

• Use antibodies specifically validated for their application

• Include comprehensive controls in all experiments

• Consider employing multiple antibodies targeting different epitopes

• Correlate antibody-based detection with orthogonal methods (e.g., mRNA analysis)

• Critically evaluate published literature in light of known specificity issues

How can researchers distinguish between different isoforms of EPOR using antibodies?

Distinguishing between EPOR isoforms presents a complex challenge requiring sophisticated methodological approaches:

• Isoform-Specific Epitope Targeting:

  Multiple EPOR isoforms exist due to alternative splicing , requiring strategic antibody selection:

  • Domain-specific antibodies: Commercial antibodies target distinct regions:

    • N-terminal region (AA 31-130)

    • Middle region (AA 301-450)

    • C-terminal region (AA 470-504)

  • Junction-specific antibodies: Custom antibodies can be generated against:

    • Unique exon-exon junctions created by alternative splicing

    • Novel sequences generated by frameshift mutations

    • Truncated termini resulting from premature stop codons

• Differential Migration Pattern Analysis:

  High-resolution electrophoresis can separate isoforms:

  • Use gradient gels (4-15%) for optimal separation

  • Compare migration patterns using antibodies targeting different domains

  • Isoforms lacking certain domains will not be detected by all antibodies

  • Post-translational modification differences between isoforms may create additional size heterogeneity

• Combined Immunological and Molecular Approaches:

  Integrating multiple techniques enhances isoform discrimination:

  • Western blot combined with RT-PCR: Correlate protein bands with specific mRNA variants

  • Immunoprecipitation + mass spectrometry: Identify peptides unique to specific isoforms

  • Expression of recombinant isoforms: Generate reference standards for each variant

  • Functional assays: Assess differential responses to EPO stimulation between isoforms

For definitive isoform identification, researchers should consider:

• First identifying the specific splice variants present at the mRNA level using RT-PCR or RNA-seq

• Developing an antibody panel targeting common and unique epitopes across these variants

• Validating antibody specificity using recombinant expression of individual isoforms

• Confirming results through orthogonal methods such as mass spectrometry

The EpoCan consortium's efforts to develop well-characterized EPOR antibodies may eventually provide more reliable tools for isoform detection .

What are the limitations of current EPOR antibodies in cancer research?

The application of EPOR antibodies in cancer research has been hampered by significant limitations that have profound implications for research validity:

To address these limitations, the field is moving toward:

• Multi-antibody approaches targeting different epitopes

• Correlation with functional assays demonstrating EPO responsiveness

• Integration of genomic, transcriptomic, and proteomic data

• Development of more specific monoclonal antibodies by consortia like EpoCan

How do I design optimal experiments to investigate EPOR signaling pathways?

Investigating EPOR signaling pathways requires careful experimental design incorporating multiple complementary approaches:

• Receptor Activation Assessment:

  Detect initial EPOR activation events:

  • Phosphorylation-specific antibodies: Target key phosphorylation sites (pTyr368, pTyr426)

  • Dimerization assays: Chemical crosslinking or FRET to monitor receptor dimerization

  • Time-course experiments: Map activation kinetics following EPO stimulation (30 seconds to 60 minutes)

  • Dose-response relationships: Determine threshold concentrations for pathway activation

• Downstream Signaling Cascade Analysis:

  EPOR activates multiple pathways that can be monitored:

  Pathway	Key Phosphorylation Targets	Functional Outcomes
  JAK2/STAT5	JAK2, STAT5	Gene transcription, proliferation
  PI3K/AKT	PI3K, AKT, mTOR	Survival, metabolism
  MAPK	ERK1/2, p38, JNK	Proliferation, differentiation

  Detection methods include:

  • Western blotting with phospho-specific antibodies

  • Flow cytometry for single-cell resolution

  • Phospho-proteomics for comprehensive pathway mapping

  • Kinase activity assays for functional confirmation

• Pathway Perturbation Strategies:

  Establish causality in signaling through targeted interventions:

  • Pharmacological inhibitors: JAK inhibitors (ruxolitinib), PI3K inhibitors (LY294002), MEK inhibitors (U0126)

  • Genetic approaches: siRNA knockdown, CRISPR knockout, or dominant-negative mutations

  • Receptor mutations: Modify key phosphorylation sites or binding domains

  • Pathway-specific reporter assays: Luciferase reporters driven by pathway-responsive elements

• Protein Interaction Studies:

  Map the EPOR signalosome:

  • Co-immunoprecipitation: Identify binding partners of activated EPOR

  • Proximity ligation assay: Visualize protein interactions in situ

  • FRET/BRET: Monitor dynamic interactions in living cells

  • Proteomics approaches: BioID or APEX proximity labeling

• Functional Readouts:

  Connect signaling events to biological outcomes:

  • Proliferation assays: [³H]-thymidine incorporation, Ki-67 staining

  • Survival assays: Annexin V/PI staining, caspase activation

  • Differentiation markers: Hemoglobin production, CD71/CD235a expression

  • Gene expression: qPCR for EPOR-responsive genes

  • Transcriptomics: RNA-seq for global expression changes

• Translational Relevance:

  Connect laboratory findings to clinical significance:

  • Patient-derived samples: Apply signaling assays to primary cells

  • Ex vivo stimulation: Test pathway activation in freshly isolated specimens

  • Correlation with outcomes: Associate signaling patterns with clinical responses

  • Therapeutic implications: Identify potential intervention points

This multi-faceted approach provides complementary lines of evidence for EPOR signaling mechanisms, helping overcome the limitations of individual techniques.

What are the emerging trends in EPOR antibody research and development?

The field of EPOR antibody research is evolving rapidly to address historical challenges and expand application possibilities. Several key trends are shaping this evolution:

• Improved Antibody Validation Standards:

  A movement toward more rigorous validation is gaining momentum:

  • Organizations like The Antibody Society are working to educate scientists about issues related to reproducibility and validation

  • Leading antibody companies (AbCam, Cell Signaling Technologies) are implementing enhanced validation protocols

  • Publishers and funders are beginning to require formal validation for all antibodies used in published research

  • The EpoCan consortium, funded by the EU, is specifically addressing EPOR antibody quality issues

• Development of Recombinant Monoclonal Antibodies:

  Technological advances are improving antibody consistency:

  • Recombinant production enables "unrivalled batch-to-batch consistency, easy scale-up, and future security of supply"

  • Companies are increasingly offering recombinant antibodies like the EPOR antibody 83056-4-PBS

  • These technologies allow precise epitope targeting and reduce lot-to-lot variability

• Expansion of Application-Specific Antibodies:

  Researchers now have access to antibodies optimized for specific techniques:

  • Matched antibody pairs for sandwich ELISA development

  • Conjugation-ready formats with BSA-free and azide-free preparation

  • Application-validated antibodies with documented performance in specific techniques

• Multi-Omics Integration:

  Antibody-based detection is increasingly complemented by other approaches:

  • Correlation of protein expression with mRNA transcripts

  • Integration with mass spectrometry-based proteomics

  • Functional validation through genetic manipulation

  • This multi-modal approach improves confidence in research findings

• Clinical Biomarker Development:

  Anti-EPOR autoantibodies are emerging as significant clinical biomarkers:

  • Associated with cardiovascular and renal outcomes in multiple patient populations

  • Standardized ELISA protocols allow comparison across studies

  • Potential for identifying high-risk patients who might benefit from tailored interventions

• Therapeutic Applications:

  Beyond research applications, therapeutic possibilities are emerging:

  • Targeting EPOR with antibodies or antibody-drug conjugates in malignancies

  • Neutralizing pathogenic anti-EPOR autoantibodies in autoimmune conditions

  • Developing agonistic antibodies as alternatives to recombinant EPO

These trends reflect a maturing field that is addressing historical challenges while expanding into new applications. The lessons learned from past EPOR antibody specificity issues have catalyzed broader improvements in antibody validation practices that benefit the entire research community.

What are the best practices for reporting EPOR antibody research results in scientific publications?

To improve reproducibility and transparency in EPOR antibody research, scientists should adopt these comprehensive reporting practices:

• Detailed Antibody Information:

  Provide complete antibody characteristics:

  • Manufacturer and catalog number (e.g., "EPOR antibody 55308-1-AP, Proteintech" )

  • Clone designation for monoclonals (e.g., "Clone VP-2E8" )

  • Host species and antibody class (e.g., "Rabbit polyclonal IgG" )

  • Target epitope location (e.g., "AA 31-130" )

  • RRID (Research Resource Identifier) when available (e.g., "AB_3086439" )

• Validation Documentation:

  Describe comprehensive validation performed:

  • Specificity controls used (positive/negative cell lines, genetic knockdown)

  • Peptide competition assays results if performed

  • Cross-reactivity testing with similar proteins

  • Comparison with other antibodies targeting different epitopes

  • References to previous validation studies when available

• Methodology Transparency:

  Detail precise experimental conditions:

  • Sample preparation methods (lysis buffers, fixation techniques)

  • Antibody dilutions used (e.g., "WB: 1:500-1:1000" )

  • Incubation conditions (time, temperature, buffer composition)

  • Detection systems employed (chemiluminescence, fluorescence)

  • Image acquisition parameters (exposure times, gain settings)

• Results Presentation:

  Provide complete experimental evidence:

  • Show full Western blots with molecular weight markers

  • Include positive and negative controls in all experiments

  • Present uncropped immunohistochemistry images with appropriate controls

  • Quantify results with statistical analysis when applicable

  • Address any unexpected findings or inconsistencies

• Historical Context:

  Acknowledge known challenges in the field:

  • Reference previous studies on EPOR antibody specificity issues

  • Discuss how your approach addresses these historical concerns

  • Compare your findings with previously published results using different antibodies

  • Consider alternative interpretations of your results

• Data Availability:

  Facilitate research reproducibility:

  • Provide raw data in supplementary materials or repositories

  • Make detailed protocols available

  • Consider sharing biological materials or reagents

  • Address reviewer concerns about antibody specificity directly